세계의 인슐린 바이오시밀러 시장 : 규모 조사, 유형별, 적응증별, 유통채널별, 지역별 예측(2024-2032년)

Global Insulin Biosimilar Market is projected to be valued at USD 2,832.39 million in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 6.2% during the forecast period, reaching USD 4867.14 million by 2032. Insulin biosimilars, which are biological products highly similar to approved insulin reference products, provide a more affordable treatment option without compromising efficacy. These biosimilars match the reference insulin in terms of safety, purity, and potency but may have minor differences in clinically inactive components. Primarily used to manage diabetes by regulating blood glucose levels, insulin biosimilars are employed in treating both Type 1 and Type 2 diabetes. By increasing market competition, biosimilars can reduce healthcare costs and enhance patient access to necessary insulin therapies.

The insulin biosimilar market is witnessing significant expansion due to the growing demand for cost-effective diabetes management solutions. The rising prevalence of diabetes globally acts as a catalyst for increasing insulin biosimilar sales. The market's growth is further propelled by the expiration of patents for several major insulin products, allowing for the development and commercialization of biosimilar versions. This surge in competition is driving down costs and improving accessibility for diabetic patients. The adoption of insulin biosimilars is particularly noteworthy in developing countries, where the prevalence of diabetes is rising, and there is a global push for improved access to affordable insulin therapy. Governments and healthcare organizations are exploring biosimilars as a means to reduce treatment costs and enhance accessibility for patients.

Advancements in biotechnology and manufacturing processes are leading to the development of high-quality insulin biosimilars that closely resemble their reference products. This is increasing acceptance of biosimilars from healthcare professionals and patients alike, providing a positive outlook for the market. Strategic collaborations and partnerships between pharmaceutical companies and healthcare providers are becoming prevalent, aiming to streamline distribution channels and expand market reach for insulin biosimilars. Overall, the insulin biosimilar market is characterized by innovation, increased competition, and a focus on improving affordability and accessibility of diabetes treatment globally. Also, 0ngoing advancements in drug delivery systems are revitalizing the insulin biosimilar market. The development of advanced solutions like insulin jet injectors, implantable pumps, and smart injectors is making insulin delivery easier and more effective. While most companies aim for a presence in developed markets, there is a huge opportunity for insulin biosimilar companies to grow in emerging countries. To succeed in these markets, biosimilar players must adopt a strategic, long-term approach focused on delivering affordable products and enhancing access in areas with significant untapped demand. This entails pursuing consistent sales growth, albeit with smaller profit margins than in developed markets.

The global insulin biosimilar industry faces significant regulatory challenges that hinder its growth. Obtaining approval for biosimilar products involves demonstrating similarity to the reference product through extensive and costly clinical trials. Biologic products, often manufactured using genetically engineered systems, pose unique challenges due to the impossibility of creating identical copies. The proprietary nature of production processes for reference products and the inherent complexity of biological molecules amplifies the difficulty of biosimilar development.

The North America are likely to dominate the Insulin Biosimilars Market owing to the presence of major manufacturers, raising awareness, and rising product launches by major players in the region. The increasing patient pool with prediabetic and diabetes is driving the growth of the market in this region. Asia-Pacific is the fastest-growing regional market for insulin biosimilars. It has the world's largest population and rapidly developing healthcare sector. The International Diabetes Federation estimated that more than 60% of the people with diabetes live in Asia, with almost one-half in China and India combined.

Major market players included in this report are:

• Eli Lilly and Company
• Sanofi SA
• BIOTON S.A.
• WOCKHARDT
• Julphar
• Biocon Ltd.
• Tonghua Dongbao
• Polfa Tarchomin S.A.
• Popular Pharmaceuticals Ltd
• SEDICO Co.

The detailed segments and sub-segment of the market are explained below:

By Type:

• Fast-acting Insulin
• Intermediate-acting Insulin
• Long-acting Insulin

By Indication:

• Diabetes Type 1
• Diabetes Type 2

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Insulin Biosimilar Market Executive Summary

• 1.1. Global Insulin Biosimilar Market Size & Forecast (2024- 2034)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Type
  • 1.3.2. By Indication
  • 1.3.3. By Distribution Channel
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Insulin Biosimilar Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Insulin Biosimilar Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Growing demand for cost-effective diabetes management solutions
  • 3.1.2. Rising prevalence of diabetes globally
  • 3.1.3. Increasing competition among pharmaceutical companies
• 3.2. Market Challenges
  • 3.2.1. Significant regulatory challenges
  • 3.2.2. High costs and complexity of biosimilar development
• 3.3. Market Opportunities
  • 3.3.1. Expansion in emerging markets
  • 3.3.2. Strategic collaborations and partnerships

Chapter 4. Global Insulin Biosimilar Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top investment opportunity
• 4.4. Top winning strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Insulin Biosimilar Market Size & Forecasts by Type 2024-2034

• 5.1. Segment Dashboard
• 5.2. Global Insulin Biosimilar Market: Type Revenue Trend Analysis, 2024 & 2034 (USD Million)
  • 5.2.1. Fast-acting Insulin
  • 5.2.2. Intermediate-acting Insulin
  • 5.2.3. Long-acting Insulin

Chapter 6. Global Insulin Biosimilar Market Size & Forecasts by Indication 2024-2034

• 6.1. Segment Dashboard
• 6.2. Global Insulin Biosimilar Market: Indication Revenue Trend Analysis, 2024 & 2034 (USD Million)
  • 6.2.1. Diabetes Type 1
  • 6.2.2. Diabetes Type 2

Chapter 7. Global Insulin Biosimilar Market Size & Forecasts by Distribution Channel 2024-2034

• 7.1. Segment Dashboard
• 7.2. Global Insulin Biosimilar Market: Distribution Channel Revenue Trend Analysis, 2024 & 2034 (USD Million)
  • 7.2.1. Hospital Pharmacies
  • 7.2.2. Retail Pharmacies
  • 7.2.3. Drug Stores
  • 7.2.4. Online Pharmacies

Chapter 8. Global Insulin Biosimilar Market Size & Forecasts by Region 2024-2034

• 8.1. North America Insulin Biosimilar Market
  • 8.1.1. U.S. Insulin Biosimilar Market
    • 8.1.1.1. Type breakdown size & forecasts, 2024-2034
    • 8.1.1.2. Indication breakdown size & forecasts, 2024-2034
    • 8.1.1.3. Distribution Channel breakdown size & forecasts, 2024-2034
  • 8.1.2. Canada Insulin Biosimilar Market
• 8.2. Europe Insulin Biosimilar Market
  • 8.2.1. U.K. Insulin Biosimilar Market
  • 8.2.2. Germany Insulin Biosimilar Market
  • 8.2.3. France Insulin Biosimilar Market
  • 8.2.4. Spain Insulin Biosimilar Market
  • 8.2.5. Italy Insulin Biosimilar Market
  • 8.2.6. Rest of Europe Insulin Biosimilar Market
• 8.3. Asia-Pacific Insulin Biosimilar Market
  • 8.3.1. China Insulin Biosimilar Market
  • 8.3.2. India Insulin Biosimilar Market
  • 8.3.3. Japan Insulin Biosimilar Market
  • 8.3.4. Australia Insulin Biosimilar Market
  • 8.3.5. South Korea Insulin Biosimilar Market
  • 8.3.6. Rest of Asia Pacific Insulin Biosimilar Market
• 8.4. Latin America Insulin Biosimilar Market
  • 8.4.1. Brazil Insulin Biosimilar Market
  • 8.4.2. Mexico Insulin Biosimilar Market
  • 8.4.3. Rest of Latin America Insulin Biosimilar Market
• 8.5. Middle East & Africa Insulin Biosimilar Market
  • 8.5.1. Saudi Arabia Insulin Biosimilar Market
  • 8.5.2. South Africa Insulin Biosimilar Market
  • 8.5.3. Rest of Middle East & Africa Insulin Biosimilar Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Eli Lilly and Company
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Sanofi SA
  • 9.3.3. BIOTON S.A.
  • 9.3.4. WOCKHARDT
  • 9.3.5. Julphar
  • 9.3.6. Biocon Ltd.
  • 9.3.7. Tonghua Dongbao
  • 9.3.8. Polfa Tarchomin S.A.
  • 9.3.9. Popular Pharmaceuticals Ltd
  • 9.3.10. SEDICO Co

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes